Business
PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares
TORONTO, June 25, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, is pleased to announce an update to its previously announced non-brokered private placement (the “Offering”) of common shares in the capital of the Company (the “Common Shares”). Pursuant to the Offering, the Company has raised gross proceeds of C$600,000 split into two tranches. Tran
About this update from Psyence Group Inc.
[{"type":"image","alt":"Psyence Group Inc.","displaySize":"","headline":null,"caption":"Psyence Group Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":73,"url":"https://media.zenfs.com/en/globenewswire.com/8c61cc4f84552088a0a6295425fca09b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/sdhaxmIhcyMdinSoiDyBzA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8c61cc4f84552088a0a6295425fca09b","width":300,"height":73}},"lazy":false},{"type":"text","content":"TORONTO, June 25, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, is pleased to announce an update to its previously announced non-brokered private placement (the “Offering”) of common shares in the capital of the Company (the “Common Shares”).","length":393,"tagName":"p","attribs":{}},{"type":"text","content":"Pursuant to the Offering, the Company has raised gross proceeds of C$600,000 split into two tranches. Tranche 1 closed today, and the Company has issued an aggregate of 4,760,000 Common Shares at a price of C$0.10 per Common Share for gross proceeds of C$476,000. Tranche 2 is anticipated to close on or about July 4, 2025 for the remaining gross proceeds of C$124,000. The Offering was originally announced on June 18, 2025. The net proceeds of the Offering will be used for general working capital purposes.","length":509,"tagName":"p","attribs":{}},{"type":"text","content":"The Offering was completed pursuant to the prospectus exemption available under Section 2.3 of National Instrument 45-106 – Prospectus Exemptions (the ‘accredited investor’ exemption) and other available exemptions under applicable securities laws. All securities issued in connection with the Offering are subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable Canadian securities laws. In the event that the Company undertakes a transaction that constitutes a fundamental change, change of business, reverse takeover, or other reviewable transaction as defined under applicable securities laws and policies of the Canadian Securities Exchange, or raises additional funds through a public offering, private placement, or other capital raise...